-
Something wrong with this record ?
Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
J. Úlehlová, B. Piskláková, E. Ivanovová, J. Procházková, P. Bradáčová, A. Kvasnička, D. Friedecký, L. Slavík
Language English Country Switzerland
Document type Journal Article
Grant support
LF 2021_001
Palacký University, Olomouc
MH CZ-DRO (FNOl, 00098892)
Ministry of Health
NLK
Directory of Open Access Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
- Publication type
- Journal Article MeSH
BACKGROUND: The effect of direct oral anticoagulants (DOAC) on laboratory tests dependent on the production of their targets, factor IIa and factor Xa, is a well-known problem and can cause both false positive and negative results. In particular, the situation in patients who develop lupus anticoagulant (LA) antibodies is highly complex. To evaluate the effectiveness of DOAC therapy in lupus-positive patients, 31 samples were enrolled in this retrospective study. All patient samples were spiked with three types of DOAC (dabigatran, DABI; rivaroxaban, RIVA; and apixaban, API) in a concentration that significantly influenced the screening test for LA and thus can mask the presence of LA. Subsequently, the DOAC was always unbound by the DOAC-Stop procedure. DOAC levels before and after binding were determined by functional assays, followed by liquid chromatography coupled with mass spectrometry (LC-MS) analysis. METHODS: The determination of DOAC levels was performed by direct thrombin assay and determination of anti-Xa activity with specific calibration as functional tests for DABI and xabans (API and RIVA). To determine concentration levels of API, DABI, and RIVA, our in-house LC-MS method was used. RESULTS: The results of LA-positive samples show significant differences between functional tests and the LC-MS method both before and after DOAC binding. CONCLUSIONS: The acute findings of the presence of LA-type antibodies fundamentally affects the determination of DOAC by functional tests, and in this case, it is necessary to use LC-MS analysis to determine the true value. If patients treated with DOAC develop LA of medium and higher titers, we do not recommend checking DOAC levels with functional tests.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22001390
- 003
- CZ-PrNML
- 005
- 20240125121937.0
- 007
- ta
- 008
- 220107s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/diagnostics11112027 $2 doi
- 035 __
- $a (PubMed)34829374
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Úlehlová, Jana $u Department of Hematology-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, 779 00 Olomouc, Czech Republic
- 245 10
- $a Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients / $c J. Úlehlová, B. Piskláková, E. Ivanovová, J. Procházková, P. Bradáčová, A. Kvasnička, D. Friedecký, L. Slavík
- 520 9_
- $a BACKGROUND: The effect of direct oral anticoagulants (DOAC) on laboratory tests dependent on the production of their targets, factor IIa and factor Xa, is a well-known problem and can cause both false positive and negative results. In particular, the situation in patients who develop lupus anticoagulant (LA) antibodies is highly complex. To evaluate the effectiveness of DOAC therapy in lupus-positive patients, 31 samples were enrolled in this retrospective study. All patient samples were spiked with three types of DOAC (dabigatran, DABI; rivaroxaban, RIVA; and apixaban, API) in a concentration that significantly influenced the screening test for LA and thus can mask the presence of LA. Subsequently, the DOAC was always unbound by the DOAC-Stop procedure. DOAC levels before and after binding were determined by functional assays, followed by liquid chromatography coupled with mass spectrometry (LC-MS) analysis. METHODS: The determination of DOAC levels was performed by direct thrombin assay and determination of anti-Xa activity with specific calibration as functional tests for DABI and xabans (API and RIVA). To determine concentration levels of API, DABI, and RIVA, our in-house LC-MS method was used. RESULTS: The results of LA-positive samples show significant differences between functional tests and the LC-MS method both before and after DOAC binding. CONCLUSIONS: The acute findings of the presence of LA-type antibodies fundamentally affects the determination of DOAC by functional tests, and in this case, it is necessary to use LC-MS analysis to determine the true value. If patients treated with DOAC develop LA of medium and higher titers, we do not recommend checking DOAC levels with functional tests.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Piskláková, Barbora $u Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, Palacký University and University Hospital Olomouc, 779 00 Olomouc, Czech Republic $7 xx0313062
- 700 1_
- $a Ivanovová, Eliška $u Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, Palacký University and University Hospital Olomouc, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Procházková, Jana $u Department of Hematology-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Bradáčová, Pavla $u Department of Hematology-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, 779 00 Olomouc, Czech Republic $7 xx0308744
- 700 1_
- $a Kvasnička, Aleš $u Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, Palacký University and University Hospital Olomouc, 779 00 Olomouc, Czech Republic $7 xx0313060
- 700 1_
- $a Friedecký, David $u Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, Palacký University and University Hospital Olomouc, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Slavík, Luděk $u Department of Hematology-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, 779 00 Olomouc, Czech Republic
- 773 0_
- $w MED00195450 $t Diagnostics $x 2075-4418 $g Roč. 11, č. 11 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34829374 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220107 $b ABA008
- 991 __
- $a 20240125121932 $b ABA008
- 999 __
- $a ind $b bmc $g 1745462 $s 1152537
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 11 $c 11 $e 20211102 $i 2075-4418 $m Diagnostics $n Diagnostics $x MED00195450
- GRA __
- $a LF 2021_001 $p Palacký University, Olomouc
- GRA __
- $a MH CZ-DRO (FNOl, 00098892) $p Ministry of Health
- LZP __
- $a Pubmed-20220107